top
Search terms
Results 1 - 10 of 24 - ordered by :
Pages: 1 2 3
Escardio

A short telomere length predicts adverse clinical outcomes following revascularisation procedures independent of age, according to a finalist abstract at the Cardiovascular Ageing and Senescence ...

Date : 31/08/2015
Escardio

The primary clinical endpoint is 12-month target lesion failure (TLF) (cardiac death, MI and target lesion revascularisation [TLR]) with secondary endpoints including death, TLR and definite/probable ...

Date : 29/08/2018
Escardio

Rome, Italy – 28 August, 2016: A therapy that uses bone-marrow stem cells to promote heart repair did not significantly improve the primary outcome over a sham procedure among patients with ...

Date : 28/08/2016
Escardio

OSLER-1 and OSLER-2 Clinical Trials Evolocumab, a monoclonal antibody that inhibits pro-protein convertase subtilisin-kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) ...

Date : 21/10/2015
Escardio

Miriam Sjåstad Langseth, MD, is a PhD candidate under the supervision of Prof. Ingebjørg Seljeflot, currently working at the Centre for Clinical Heart Research, Ullevål University ...

Date : 09/04/2019
Escardio

(1) The off-label use of the drug led to worse clinical outcomes including a doubled risk of hospitalisation compared to placebo. “Valvular disease is considered the next cardiac epidemic ...

Date : 28/08/2017
Escardio

Transcatheter aortic valve implantation (TAVI) is safe and effective in nonagenarians, according to research presented at ESC Congress today.1 The observational study found that nonagenarians who ...

Date : 28/08/2017
Escardio

Promising early findings with the V-LAP™ system in patients with chronic heart failure Prior studies using implantable haemodynamic monitors have demonstrated that pressure-guided heart failure ...

Date : 28/05/2019
Escardio

The addition of intravenous (IV) N-acetylcysteine (NAC) to IV glyceryl trinitrate (GTN) significantly reduced infarct size by approximately one third in patients undergoing percutaneous coronary ...

Date : 28/08/2016
Escardio

The GISSI-HF trial found rosuvastatin (10 mg daily) did not affect clinical outcomes in patients with chronic heart failure of any cause, in whom the drug seemed to be safe.   Large observational ...

Date : 31/08/2008